Articles tagged with: ViiV Healthcare
Espanol »
Los resultados preliminares de un estudio clínico en fase 2b aún en curso indican que el inhibidor de la transcriptasa inversa lersivirina, aún en investigación, podría ser tan segura y eficaz como la Sustiva en personas con VIH que nunca han tomado medicamentos antirretrovirales.
“La lersivirina pertenece a la nueva generación de inhibidores no nucleósidos de la transcriptasa inversa … [que] tiene una actividad potente contra el VIH”, dijo el Dr. Anton Pozniak, que presentó los resultados en la 6ª Conferencia Internacional de la Sociedad del SIDA sobre Patogénesis, Tratamiento…
Espanol »
Los resultados preliminares de un estudio clínico en fase 2b aún en curso indican que el dolutegravir, un nuevo inhibidor de la integrasa en desarollo, tomado una vez al día, puede ser tan seguro y eficaz como la Sustiva en las personas con VIH que no han recibido tratamiento previo.
“El dolutegravir administrado una vez al día… mostró una respuesta rápida y sostenida en todas las dosis exploradas hasta la semana 48”, dijo el Dr. Jan van Lunzen, que presentó estos resultados en la 6ª Conferencia Internacional de la Sociedad…
News »
Government Pushes States To Reconsider HIV Criminal Laws – The federal government has begun implementing measures to push states to reevaluate and repeal HIV-specific criminal laws, many of which were passed before researchers knew how HIV was transmitted. The President’s Advisory Council on HIV/AIDS (PACHA) agreed unanimously last week to address such laws in its implementation of the National HIV/AIDS Strategy. In addition, Congresswoman Barbara Lee has drafted legislation that states that laws criminalizing HIV exposure or transmission are a violation of HIV-positive individuals’ human rights. Lee also calls for a review of current state and federal criminal laws on HIV. Activists praised the measures, stating that HIV-specific laws are discriminatory and promote stigma against people with HIV. For more information, please see the article in The Washington Independent.
ViiV Healthcare Sues Teva Pharmaceuticals Over Generic Epzicom – ViiV Healthcare is suing generic drug maker Teva Pharmaceuticals for infringing on a patent for Epzicom (abacavir/lamivudine). Teva has applied for permission from the U.S. Food and Drug Administration to produce generic Epzicom tablets; however, ViiV Healthcare states that this violates a 2002 patent on Epzicom that does not expire until 2016. ViiV Healthcare is seeking to block Teva from producing generic Epzicom and has also requested damages if the company sells a generic version of the drug. ViiV Healthcare is a joint venture by U.S. pharmaceutical companies Pfizer and GlaxoSmithKline. For more information, please see the article in Bloomberg.
AmfAR Launches “Making AIDS History” Campaign – The Foundation for AIDS Research (amfAR) has launched a new campaign called “Making AIDS History” to document the progress that has been made in the fight against HIV and AIDS in the past 30 years. The campaign’s website features short video profiles of men, women, and children who have been affected by HIV, as well as longer interviews with some of the individuals in the video profiles. The campaign is part of a fundraising effort to raise money for amfAR, which focuses on research to help cure HIV. For more information, please see the Making AIDS History website.
Bristol-Myers Squibb Announces Winners Of “Fight HIV Your Way” Contest – Bristol-Myers Squibb has announced the winners of the 2011 “Fight HIV Your Way” contest, in which people who have HIV or have been affected by HIV submitted photos and essays to show how they are fighting the virus. The ten winners will have their works incorporated into an American Dance Theatre work by Alvin Ailey, which will debut on World AIDS Day, December 1, 2011. For more information or to see the winning entries, please see the Fight HIV Your Way website or the Bristol-Myers Squibb press release.
Featured, Headline, News »
Interim results from an ongoing Phase 2b clinical trial indicate that once-daily dolutegravir, an investigational new integrase inhibitor, may be as safe and effective as Sustiva in people with HIV who have not previously been treated.
“Dolutegravir administered once daily…showed a rapid and sustained response at all doses explored through week 48,” said Dr. Jan van Lunzen, who presented the results yesterday at the 6th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention (IAS 2011).
“The drug in all dose groups was well tolerated, with fewer discontinuations occurring…
Headline, News »
Interim results from an ongoing Phase 2b clinical trial show that the investigational non-nucleoside reverse transcriptase inhibitor lersivirine may be as safe and effective as Sustiva in people with HIV who have not previously taken antiretrovirals.
“Lersivirine is a next generation non-nucleoside reverse transcriptase inhibitor…[that] has potent activity against HIV,” said Dr. Anton Pozniak, who presented the results today at the 6th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention (IAS 2011).
“Both lersivirine doses [tested] achieved similar viral load suppression to [Sustiva],” he added.
Dr. Pozniak suggested…